Poland’s fledgling biotech company, Mabion SA, believes it is among the leaders in the race to develop a biosimilar version of Roche's monoclonal antibody, MabThera/Rituxan (rituximab), for Europe, but it needs to finalize a tie-up with a marketing partner or partners fast, as they will need time to prepare to compete against biosimilar heavyweights that are also developing versions of the blockbuster TNF-inhibitor.
Mabion expects to administer the last doses of its biosimilar rituximab, MabionCD20, in pivotal clinical studies this summer – in...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

